Sanofi’s eczema drug hits pri­ma­ry end­point in PhI­Ib tri­al, plans un­der­way for PhI­II in 2024

Sanofi’s an­ti-OX40L an­ti­body, am­lite­limab, passed a 390-pa­tient Phase IIb tri­al by hit­ting the pri­ma­ry end­point, with pa­tients see­ing up to a 61.5% im­prove­ment on a scale used to mea­sure eczema sever­i­ty, the com­pa­ny said at the Eu­ro­pean Acad­e­my of Der­ma­tol­ogy and Venere­ol­o­gy Con­gress.

Sanofi rolled out de­tailed da­ta from its dose-rang­ing STREAM-AD tri­al on Fri­day, paving the way for a Phase III study in the first half of next year and bol­ster­ing the com­pa­ny’s im­munol­o­gy port­fo­lio. Sanofi first got its hands on the drug when it bought out Kymab in 2021 for $1.5 bil­lion, with am­lite­limab as the top can­di­date in the deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER